title: Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.
abstract: There is no approved therapy for hepatitis C virus (HCV) infection after kidney transplantation, and no data regarding the use of new-generation direct antiviral agents (DAAs) have been published so far. The aims of this pilot study were to assess the efficacy and safety of an interferon-free sofosbuvir-based regimen to treat chronic HCV infection in kidney transplant recipients. Twenty-five kidney transplant recipients with chronic HCV infection were given, for 12 (n = 19) or 24 weeks (n = 6), sofosbuvir plus ribavirin (n = 3); sofosbuvir plus daclatasvir (n = 4); sofosbuvir plus simeprevir, with (n = 1) or without ribavirin (n = 6); sofosbuvir plus ledipasvir, with (n = 1) or without ribavirin (n = 9); and sofosbuvir plus pegylated-interferon plus ribavirin (n = 1). A rapid virological response, defined by undetectable viremia at week 4 after starting DAA therapy, was observed in 22 of the 25 patients (88%). At the end of therapy, HCV RNA was undetectable in all patients. At 4 and 12 weeks after completing DAA therapy, all had a sustained virological response. The tolerance to anti-HCV therapy was excellent and no adverse event was observed. A significant decrease in calcineurin inhibitor levels was observed after HCV clearance. New-generation oral DAAs are efficient and safe to treat HCV infection after kidney transplantation.
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.|INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.|Université Paul Sabatier, Toulouse, France.
authors.forename: N
authors.initials: N
authors.lastname: Kamar
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: O
authors.initials: O
authors.lastname: Marion
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.|INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.|Université Paul Sabatier, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Rostaing
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: O
authors.initials: O
authors.lastname: Cointault
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: D
authors.initials: D
authors.lastname: Ribes
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Lavayssière
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Esposito
authors.affiliation: Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
authors.forename: A
authors.initials: A
authors.lastname: Del Bello
authors.affiliation: Department of Hepatology and Gastroenterology, Toulouse, France.
authors.forename: S
authors.initials: S
authors.lastname: Métivier
authors.affiliation: Department of Hepatology and Gastroenterology, Toulouse, France.
authors.forename: K
authors.initials: K
authors.lastname: Barange
authors.affiliation: INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.|Université Paul Sabatier, Toulouse, France.|Laboratory of Virology, CHU Purpan, Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Izopet
authors.affiliation: Université Paul Sabatier, Toulouse, France.|MR 152 IRD-Toulouse 3 University, Toulouse, France.|Internal Medicine-Digestive Department, CHU Purpan, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Alric
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006085:Graft Survival / Q000187:drug effects*; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000601:surgery; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D012307:Risk Factors; D012449:Safety; D000069474:Sofosbuvir / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D000069474:Sofosbuvir
keywords: clinical research / practice; infection and infectious agents; infectious disease; kidney disease: infectious; kidney transplantation / nephrology; viral: hepatitis C